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tality by surgery 50% versus no surgery 76%. The number of
patients who had HSCT increased over time: 30days  7,
30days–100days  9, and 	100days  15. Caspofungin used in
23%. Concommitant infection seen in 60% of patients. Mortality
for patients treated with amphotericin was 	75%. Discussion:
The characteristics of patients and outcomes for voriconazole ex-
posure are typical for Zygomycosis infection from any cause in
addition to steroid and Rhizopus species. Reports are from diverse
geographical sites around the USA.Voriconazole is being used off
label as prophylaxis without data to support efﬁcacy. One institu-
tion reported voriconazole an independent risk factor for Zygo-
mycosis. Breakthrough infections are common with other azoles,
so our ﬁndings here are not unexpected. Trials are needed deter-
mine if cases of Zygomycosis with voriconazole are offset by a
more pronounced decrease in Aspergillosis and other voriconazole
susceptible organism. We urge caution with indiscriminate pro-
phylaxis and empiric treatment. Diagnosis of infection with prior
voriconazole exposure requires appropriate treatment with Zygo-
mycosis coverage.
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NAUSEA AND VOMITING (N AND V) IN BONE MARROW TRANSPLANT
(BMT) PATIENTS—AN INVESTIGATION OF THE INCIDENCE, TIMING,
AND RELATED FACTORS
Lees, J., Marotti, R. Royal Adelaide Hospital, Pharmacy Department,
Adelaide, South Australia, Australia.
Background: Patients receiving high dose chemotherapy
(HDCT) pre-BMT are at risk of N and V from multiple causes—
highly emetic conditioning chemotherapy  Total Body Irradia-
tion; prior chemotherapy experiences; concomittant medications
such as anti-infectives, opioid analgesics, immunosuppressants
which may add to N and V; regimen related toxicity such as
mucositis may play a role; nasoenteric feeding (N/E) is sometimes
used. Whereas evidence based antiemetic guidelines are available
for standard chemotherapy, they have not yet been accepted for
BMT. Information on our own BMT patients had not been col-
lected. Aim: To investigate the incidence, timing, and factors
affecting N and V in BMT patients. Methods: Patients were
interviewed to obtain consent, history of previous emesis and their
risk factors for emesis. HDCT started on day 7 to 2 depending
on protocol, and transplant on day 0. Patients were given a diary
and education on how to record N and V daily until discharge.
Standard antiemetics were given during HDCT. Chemotherapy,
nursing emesis scores, all medications, incidence of mucositis, and
use of N/E feeding was recorded. Results: There were 21 patients,
52% male, mean age 51. Conditioning regimens included high
dose melphalan, cyclophosphamide/TBI, Bu/Cy/Etoposide, and
BEAM. Most patients had experienced prior CT-induced nausea
(81%) and vomiting (62%). Patients did not all record N and V
every day for the following reasons: too unwell (febrile, severe
mucositis etc), forgot, lost interest. Eight patients (38%) had no
vomiting at all during this study. Incidence of vomiting of any
grade peaked on day 5 (36% patients). Nausea of any grade was up
to 71% on days 3 and 4. Nausea persisted in 	50% of reporting
patients on day 12, and in 4 patients (all receiving melphalan) on
day 25. Prior chemotherapy-induced emesis was a signiﬁcant pre-
dictor of at least one vomiting episode (P  .01). Other factors
were not signiﬁcant. Conclusions: Nausea and vomiting are un-
resolved toxicities in BMT. Methodology for collecting N and V
information will be modiﬁed for an on-going study.
503
RABBIT ANTI-THYMOCYTE GLOBULIN (RATG;THYMOGLOBULIN)
PHARMACOKINETICS IN PEDIATRIC PATIENTS RECEIVING A HEMATO-
POIETIC STEM CELL TRANSPLANT (HSCT)
Hale, G.A., Call, S.K., Handgretinger, R., Horwitz, E., Kasow, K.,
Barﬁeld, R., Yusuf, U., Woodard, P., Leung, W., Rodman, J. St. Jude
Children’s Research Hospital, Memphis, TN.
Objective: The pharmacokinetics of active and total rATG were
determined in children with hematologic malignancies receiving a
HSCT. Methods: Pediatric patients (n  5) undergoing HSCT
with a matched unrelated donor (MUD), non-T cell depleted
graft received 1 mg/kg rATG on day 4, then 3 mg/kg on days
3, 2, 1 (total dose 10 mg/kg). Blood samples (n  14) were
obtained from each patient at baseline, 24 hours post dose, day
0, 1, 3, 5, 7, and weeks 2, 4, 8, 12, and 24). Total rATG
by ELISA and active rATG by FACS were assayed at each time
point. Conditioning regimen consisted of fractionated TBI
(day-8 to -5) thiotepa (5 mg/kg q12h  2 doses day &minus4),
cyclophosphamide (60 mg/kg  2 days 3, 2) with cyclospor-
ine beginning day 2. Results: Intersubject variability was
substantial with a 4-fold range for total and active rATG on day
0. Total rATG was measurable in all patients through week 4
and in 4 of 5 patients at 8 weeks. Mean day 0 total rATG was 47
mcg/ml (CV 49%; range 22.6-80.7) and on day 28 was 15.5
mcg/ml (CV 41%; range 5.1-20.6). Active rATG was measur-
able in all patients through week 2, 4 of 5 patients at week 4, and
was undetectable (0.2 mcg/ml) in all patients at 8 weeks. Mean
day 0 active rATG was 2.1 mcg/ml (CV 49%, range 0.95-3.74)
and on day 28 was 0.51 mcg/ml (CV 102%; range 0.2-1.28).
Median percent active rATG after dose 1 was 14% and progres-
sively decreased during rATG administration to 4-5% on day 0
and remained similar through week 2. Median half-life for total
rATG is 15 days but could not be reliably estimated for active
rATG. All patients engrafted by day 23 (ANC 	 500), en-
grafted platelets by day 49 (20 K). There were no episodes
of grade 3-4 GVHD, 1 patient developed grade 2 GVHD, and
no grade 3 or 4 adverse rATG related events or serious infec-
tions. Conclusions: When compared to previously published
adult data (Waller et al; Biol Blood Marrow Transplant 9:460,
2003), pediatric patients have substantially lower total and active
rATG despite receiving higher doses. Differences in patient
population, dose, schedule, and sampling make comparisons
with prior studies difﬁcult. However, these initial data in chil-
dren suggest signiﬁcant differences in rATG pharmacokinetics
from adult transplant patients that preclude extrapolation of
pediatric dose regimens from adult studies.
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